# Hims & Hers Health

Type: Company (HIMS)

Source: GetYourBrief — https://getyourbrief.com/entity/hims-hers-health
Canonical HTML page: https://getyourbrief.com/entity/hims-hers-health

## Timeline

- **2026-Q2 (projected)**: Product Transition — Hims & Hers expected to fully phase out compounded GLP-1s in favor of branded Ozempic.
- **2026-03-09**: Settlement & Collaboration — Hims & Hers and Novo Nordisk announce the end of litigation and the start of a commercial partnership.
- **2026-03-09**: Settlement Reached — Both companies announce an end to litigation and the start of a strategic collaboration.
- **2026-03-09**: Strategic Settlement — Hims & Hers and Novo Nordisk announce a distribution partnership and lawsuit dismissal.
- **2026-03-09**: Market Surge — HIMS stock skyrockets 41% with record-breaking trading volume.
- **2026-03**: Settlement Reached — Hims & Hers agrees to stop selling compounded GLP-1s to resolve legal disputes.
- **2025-10-15**: Supply Stabilization — FDA indicates that semaglutide shortages are easing, increasing legal pressure on compounders.
- **2025-Q4**: Legal Friction — Novo Nordisk files patent infringement lawsuits against telehealth providers selling compounded GLP-1s.
- **2025**: Litigation Surge — Novo Nordisk and Eli Lilly file multiple lawsuits against compounding pharmacies and telehealth firms.
- **2025-Q1**: Supply Stabilization — Novo Nordisk increases supply of branded Wegovy, challenging the legal basis for compounding.
- **2024**: FDA Shortage Updates — FDA begins removing specific GLP-1 dosages from the national shortage list.
- **2024-05-20**: Hims & Hers GLP-1 Launch — Hims & Hers announces the launch of compounded GLP-1 injections at a significant discount to brand names.
- **2024-05**: HIMS Launches GLP-1s — Hims & Hers enters the weight-loss market with compounded GLP-1 offerings.
- **2024-05**: Hims Enters Market — Hims & Hers launches its compounded semaglutide offering at a lower price point.
- **2023-Q4**: Litigation Begins — Novo Nordisk starts filing lawsuits against compounding pharmacies for IP infringement.

## Recent coverage (15 stories, network-wide)

### Beachbody digital subs -19% to 760K; Hims +19%
2026-08-18 00:45:41 · Sector: saas · Sentiment: Positive · Impact: 6/10 · Sources: 2

Subscription and digital revenue trends across Beachbody, Purple, and Hims show churn management is now a core operational focus. Beachbody digital subscriptions fell 19.1% to 760,000 while Hims added 452,000 subscribers to reach 2.89 million.
Full story: https://getsaasbrief.com/story/saas-subscription-q2-2026-digital-revenue

### Beachbody revenue drops 22%, Purple DTC rises 3.4%
2026-08-18 00:45:24 · Sector: retail · Sentiment: Positive · Impact: 6/10 · Sources: 2

Beachbody's Q2 revenue fell 22.4% to $49.6M as it shifts from MLM to omnichannel, while Purple grew direct-to-consumer revenue 3.4% to $60.9M. Both show margin gains from restructuring but face weaker wholesale demand.
Full story: https://getretailbrief.com/story/retail-beachbody-purple-q2-2026

### Hims Q2 revenue hits $753M; Alcon eye care grows 7%
2026-08-18 00:45:06 · Sector: health · Sentiment: Positive · Impact: 6/10 · Sources: 2

Hims & Hers posted 38% revenue growth and 2.89M subscribers while absorbing $81M in nonrecurring charges, and Alcon's core EPS rose 9% to $0.84. Telehealth demand and ocular health innovation are driving divergent profit outcomes.
Full story: https://gethealthbrief.com/story/health-hims-alcon-q2-2026-earnings

### Hims revenue +38% to $753M; Alcon EPS $0.84
2026-08-18 00:44:48 · Sector: finance · Sentiment: Positive · Impact: 6/10 · Sources: 2

A cross-sector Q2 2026 earnings read shows Hims & Hers growing 38% to $753M and Alcon raising EPS guidance, while Beachbody and Purple manage revenue declines. Plug Power's margin improvement and reduced cash burn stand out for risk-tolerant investors.
Full story: https://getfinancebrief.com/story/finance-q2-2026-earnings-roundup

### Plug Power gross margin improves to -0.9% from -30.7%
2026-08-18 00:44:32 · Sector: climate · Sentiment: Positive · Impact: 6/10 · Sources: 2

Plug Power's revenue rose 9% sequentially to $178.3M, gross margin improved to -0.9% from -30.7%, and GenDrive deployments surged 125% to 1,666 units. The company raised full-year revenue growth guidance to 15-16%.
Full story: https://getclimatebrief.com/story/climate-plug-power-q2-2026

### Alcon core EPS up 9% to $0.84; PowerVision charge $402M
2026-08-18 00:44:12 · Sector: bio · Sentiment: Positive · Impact: 6/10 · Sources: 2

Alcon posted 7% constant-currency sales growth and raised full-year core EPS guidance to 12-15% growth, but took a $402M noncash charge to discontinue PowerVision. Hims & Hers added branded weight-loss momentum with $753M revenue.
Full story: https://getbiobrief.com/story/bio-alcon-q2-2026-power-vision

### Novo Nordisk’s Oral GLP-1 Approval Signals New Era for Obesity Treatment
2026-03-17 15:59:54 · Sector: finance · Sentiment: Positive · Impact: 7/10 · Sources: 2

The FDA approval of Novo Nordisk's first oral GLP-1 for weight loss has sparked a rally in NVO shares, offering a needle-free alternative to Wegovy. This development, coupled with a strategic partnership with Hims & Hers, positions the company to maintain its dominant market share against rising competition.
Full story: https://getfinancebrief.com/story/novo-nordisk-oral-glp-1-approval-market-impact

### Hims & Hers Surges 41% on Landmark Novo Nordisk GLP-1 Distribution Deal
2026-03-10 00:21:10 · Sector: finance · Sentiment: Positive · Impact: 7/10 · Sources: 3

Hims & Hers Health shares skyrocketed following a strategic partnership with Novo Nordisk to distribute branded GLP-1 medications, effectively ending a high-stakes patent dispute. The agreement shifts the telehealth provider's weight-loss strategy from controversial compounded versions to FDA-approved Ozempic, significantly de-risking its long-term growth profile.
Full story: https://getfinancebrief.com/story/hims-hers-novo-nordisk-glp1-deal

### Hims & Hers Surges 41% on Landmark GLP-1 Supply Deal with Novo Nordisk
2026-03-10 00:20:37 · Sector: bio · Sentiment: Positive · Impact: 7/10 · Sources: 3

Hims & Hers Health shares skyrocketed 41% following a strategic agreement with Novo Nordisk to distribute branded GLP-1 medications, including Ozempic, directly through its telehealth platform. The deal effectively ends a high-stakes patent dispute and transitions the company away from controversial compounded formulations toward FDA-approved branded therapies.
Full story: https://getbiobrief.com/story/hims-hers-novo-nordisk-glp1-partnership

### Hims & Hers Surges 41% on Landmark GLP-1 Distribution Deal with Novo Nordisk
2026-03-10 00:20:04 · Sector: health · Sentiment: Positive · Impact: 7/10 · Sources: 3

Hims & Hers Health has secured a strategic partnership with Novo Nordisk to distribute branded GLP-1 medications, effectively ending a high-stakes patent dispute. The deal marks a pivotal shift for the telehealth provider from compounded alternatives to FDA-approved Ozempic, triggering a massive 41% rally in its share price.
Full story: https://gethealthbrief.com/story/hims-and-hers-novo-nordisk-glp1-partnership

### Hims & Hers to Halt Compounded GLP-1 Sales Following Legal Settlement
2026-03-09 17:34:05 · Sector: health · Sentiment: Negative · Impact: 6/10 · Sources: 2

Hims & Hers Health has agreed to cease the sale of compounded GLP-1 medications as part of a legal settlement, marking a significant shift in its weight-loss business strategy. This move follows mounting pressure from pharmaceutical manufacturers and highlights the tightening regulatory environment for telehealth platforms leveraging drug shortages.
Full story: https://gethealthbrief.com/story/hims-hers-settles-glp1-lawsuit-compounding

### Hims & Hers and Novo Nordisk Settle GLP-1 Dispute, Launch Collaboration
2026-03-09 17:33:03 · Sector: bio · Sentiment: Positive · Impact: 6/10 · Sources: 5

Hims & Hers Health and Novo Nordisk have settled their legal dispute regarding compounded weight loss medications, transitioning into a strategic collaboration. This agreement marks a significant shift in the GLP-1 market, moving from litigation to a partnership that could broaden access to semaglutide treatments.
Full story: https://getbiobrief.com/story/hims-hers-novo-nordisk-settlement-glp1

### Hims & Hers and Novo Nordisk Settle GLP-1 Dispute, Pivot to Partnership
2026-03-09 17:32:30 · Sector: health · Sentiment: Positive · Impact: 6/10 · Sources: 5

Hims & Hers Health and Novo Nordisk have resolved their legal dispute over compounded weight loss medications, announcing a surprise collaboration instead. This settlement marks a significant shift in the GLP-1 market, moving from aggressive litigation to a strategic alliance between a telehealth leader and a pharmaceutical giant.
Full story: https://gethealthbrief.com/story/hims-hers-novo-nordisk-settlement-collaboration

### Hims & Hers Health to Halt Compounded GLP-1 Sales in Landmark Settlement
2026-03-09 17:30:26 · Sector: legal · Sentiment: Negative · Impact: 6/10 · Sources: 2

Hims & Hers Health has agreed to cease the sale of compounded GLP-1 medications as part of a legal settlement, marking a significant shift in the telehealth landscape. This move follows intense regulatory scrutiny and litigation regarding the legality of compounding patented weight-loss drugs during supply shortages.
Full story: https://getlegalbrief.com/story/hims-hers-glp1-settlement-regulation

### Hims & Hers and Novo Nordisk Settle GLP-1 Litigation, Pivot to Collaboration
2026-03-09 17:29:52 · Sector: legal · Sentiment: Positive · Impact: 6/10 · Sources: 5

Hims & Hers Health and Novo Nordisk have reached a settlement to end their legal dispute over compounded weight loss medications. The agreement transitions the relationship from adversarial litigation to a strategic collaboration, potentially reshaping the telehealth distribution model for GLP-1 drugs.
Full story: https://getlegalbrief.com/story/hims-hers-novo-nordisk-glp1-settlement-collaboration

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.